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Original StudieS
Background: Sepsis and meningitis in neonates and infants are a source 
of substantial morbidity, mortality and economic loss. The objective of this 
review is to estimate the acute costs associated with treating sepsis, men-
ingitis and meningococcal septicemia, in neonates and infants, worldwide.
Methods: The electronic databases Medline, Embase and EconLit were 
searched and exported on November 24, 2018. Studies that reported an 
average hospitalization cost for confirmed cases of sepsis, meningitis or 
meningococcal septicemia were eligible for our review. Descriptive data 
were extracted and reported costs were inflated and converted. A narrative 
synthesis of the costs was conducted.
Results: Our review identified 20 studies reporting costs of sepsis, menin-
gitis and/or meningococcal septicemia. Costs ranged from $55 to $129,632 
for sepsis and from $222 to $33,635 for meningitis (in 2017 US dollars). 
One study estimated the cost of meningococcal septicemia to be $56,286. 
All reported costs were estimated from the perspective of the healthcare 
provider or payer. Most studies were from the United States, which also had 
the highest costs. Only a few studies were identified for low- and middle-
income countries, which reported lower costs than high-income countries 
for both sepsis and meningitis.
Conclusions: Sepsis and meningitis in neonates and infants are associated 
with substantial costs to the healthcare system and showed a marked dif-
ference across global income groups. However, more research is needed 
to inform costs in low- and middle-income settings and to understand the 
economic costs borne by families and wider society.
Key Words: neonate, infants, sepsis, meningitis, costs
(Pediatr Infect Dis J XXX;XX:00–00)
Infectious diseases among neonates and infants constitute a con-siderable global health burden. Despite significant strides in 
enhancing childhood survival over recent decades, there remain 
around 5.4 million deaths annually in children under 5, with 2.5 
million deaths amongst neonates.1 An estimated one-third of neo-
natal deaths are caused by infectious causes, with limited data on 
the etiological agents behind these infections.2 Meningitis and 
sepsis are consequences of several invasive bacterial species such 
as group B streptococcus, Neisseria meningitides and Streptococ-
cus pneumoniae and are particularly common in young children. 
They have a high case-fatality risk, collectively accounting for an 
estimated 3.7 deaths per 1000 live births,3 and impact substantially 
on child survival where 7% of under-5 mortality is attributable to 
these conditions.3 They also commonly cause long-term physical 
and neurological sequelae among survivors.
Costs of treating sepsis and meningitis can vary according 
to healthcare setting, age and severity of infection. Costs incurred 
in treating meningitis significantly decrease with increasing age of 
child, as well as increasing certainty of diagnosis.4 A similar trend 
is seen with sepsis where infants can incur almost double the cost of 
treatment compared to children over one year old.5 This is because of 
the severity of infection in younger children who have underdevel-
oped immune systems compared to older children. Although existing 
studies report a wide range of costs across low-, middle- and high-
income countries, the literature has not been reviewed systematically 
to present a global comparison of costs incurred as a result of sep-
sis and meningitis in neonates and infants. Moreover, it is estimated 
that three-quarters of reported deaths amongst under-5s occur in the 
first year of life,1 requiring a better understanding of the age-specific 
attributable costs, where studies typically aggregate costs for all chil-
dren under 5 despite variations in setting, severity and age.
Much of the burden of sepsis and meningitis could be pre-
vented or reduced in severity by measures such as current and 
pipeline vaccines, diagnostics and antibiotics. In low- and middle-
income settings it has been proposed that scaling up coverage of 
facility-based healthcare services during the antenatal period, labor 
and childbirth could avert close to 70% of neonatal deaths by 2025.6 
However, investment in the optimal prevention and treatment strate-
gies require good estimates of the cost-effectiveness of the inter-
ventions, which in turns requires understanding the economic bur-
den of sepsis and meningitis. As important short-term landmarks 
of invasive neonatal and infant disease, costs of treating meningitis 
and sepsis can instruct economic evaluations conducted by different 
stakeholders in order to optimize scarce health care resources.
The objective of this study was to conduct a systematic 
review to identify and assess the worldwide evidence on the costs 
of treating sepsis, meningitis and meningococcal septicemia, 
among neonates and infants under one.
MATERIALS AND METHODS
Search Strategy
Our review was carried out in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses guide-
lines, and a protocol for the review was registered in International 
prospective register of systematic reviews (CRD42019120253). We 
performed a systematic search of the Medline, Embase and Econlit 
bibliographic databases to identify studies reporting the acute costs 
of treating neonates and infants under 1 year old with confirmed 
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sepsis and meningitis. The search strategy combined index terms 
and key words, including “infant,” neonate,” “sepsis,” “meningi-
tis” and “cost,” and the full search terms are provided in Text, Sup-
plemental Digital Content 1, http://links.lww.com/INF/D666. The 
search was conducted on November 24, 2018.
Selection Criteria
Since there is no single accepted clinical definition of 
sepsis,7 sepsis and meningitis were defined according to the case 
definition used by the authors of each article. Cases with severe 
septic shock were also included in our case definition; however, 
we excluded cases of aseptic meningitis and rule-out sepsis. Where 
studies ascertained cases through coding systems, such as the 
International Classification of Diseases, we assumed that coding 
correctly reflected clinical presentation and confirmed laboratory 
isolation of infectious organisms. Cases with meningococcal sep-
ticemia were also considered for our review and were reported as a 
subset of meningitis. Our selection was limited to human subjects 
and studies that estimated costs based on unit costs or resource 
utilization measures derived from primary data collection or pre-
viously unanalyzed data from healthcare information systems. We 
excluded review articles and reported costs that were not directly 
attributable to the age group and/or exposure of interest. No limits 
were applied to conference abstracts or non-English studies.
Study Selection and Data Extraction
Search results were imported into a Reference Manager 
(Mendeley), and duplicate records were manually detected and 
removed. Two reviewers, O.S. and C.M., screened study titles and 
abstracts, and the full text of potentially eligible studies to assess 
their eligibility for final inclusion. Authors were contacted where 
data was missing or clarifications on reported costs were needed. 
The studies’ descriptive characteristics, including study design, 
data sources, costing methodology and any underlying comorbidi-
ties, were recorded. We extracted all reported costs associated with 
an acute hospital episode for our exposure of interest, regardless 
of whether they fell on the healthcare provider, third-party payer, 
patient/household or society. Where available, we also extracted 
individual costs for different categories of health resources (eg, 
drugs and diagnostics) as well as the average length of stay (LOS).
Data Analysis and Synthesis
Reported costs were inflated to the year 2017 using the 
country-specific World Bank gross domestic product deflator.8 For 
studies that reported costs in local currencies other than US Dollars 
the values were first inflated then converted into US Dollars using 
the historical foreign exchange rates of the US Federal Reserve for 
2017.9 Values were also converted to international dollars using the 
ratio of the Purchasing Power Parity conversion factor to market 
exchange rates for 2017.10
Extracted studies were subgrouped according to the World 
Bank Country and Lending Group categorization for 2019.11
Quality Assessment
Criteria to assess methodological strengths and weaknesses 
in study design were adapted from a previous meningitis costing 
review by Portnoy et al12 We used the 5-point scale after revising 
the methodological criteria to better reflect the global focus and 
selection criteria of our review (ie, disregarding country setting 
and costs based on interviews). The 5 selected factors that increase 
the assessment of a study’s quality were (1) using a bottom-up 
approach to estimating costs, (2) a study sample that exceeds 100 
patients, (3) reporting both direct and indirect costs, (4) inclusion 
of a specific clinical case definition for sepsis and/or meningitis 
and (5) the specification of measures taken by authors to account 
for acknowledged uncertainties and biases. A study was awarded 1 
point for each of these factors resulting in a total score between 0 
and 5. No points were awarded for a factor that was unclear from 
the authors’ description of the study.
RESULTS
Study Selection
Figure, Supplemental Digital Content 2, http://links.lww.
com/INF/D667 is a Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses flow diagram showing the process by 
which studies were selected. Our search yielded 3441 studies after 
searching our selected databases.
A total of 20 studies met the inclusion criteria of our 
review,4,5,13–30 and the main study characteristics are summarized in 
Table 1. The included studies had very limited geographic coverage 
with cost estimates for sepsis from 5countries and meningitis esti-
mates from only 2 countries. Overall, 13 studies were from North 
America with only 4 studies from East Asia, 1 study from Southern 
Asia, 1 study from North Africa and 1 study from Europe. There were 
no study studies from either Latin America or sub-Saharan Africa. 
Five studies were from middle-income countries and 15 studies from 
high-income settings. No studies were from low-income countries.
Each study included one or more treatment cost estimates 
for sepsis, meningitis and/or meningococcal septicemia, and overall 
24 cost estimates were reported across the 3 diseases. Four studies 
reported costs for treating patient with sepsis in populations with par-
ticular comorbidities. All the studies reported costs from the healthcare 
provider perspective, with the exception of 3 studies, which provided a 
payer’s perspective.23,27,28 There were no studies that included costs from 
a wider societal perspective, and none of the included studies reported 
long-term costs associated with sequelae of sepsis or meningitis.
Studies reported a mixture of mean and median costs. Where 
a study reported both estimates, we have presented the mean cost 
in Figures 1 and 2 and include the median in Table, Supplemental 
Digital Content 3, http://links.lww.com/INF/D668.
Costs Related to Sepsis
There were 17 estimates for sepsis-related costs (see Fig. 1).
Average Cost of Hospitalization
Among the reported estimates, 14 studies gave an average 
cost for an entire hospital episode. The costs of treating sepsis 
per patient ranged from $55 in India13 to $129,632 in the United 
States.18 The mean cost weighted by study sample size (and ignor-
ing those studies that only reported median costs) was $55 in lower-
middle income countries, $2192 in upper-middle income countries 
and $82,328 in high-income countries.
Component Costs
In addition to the total cost of hospitalization, 2 studies 
separately reported the average cost of antimicrobial therapy per 
patient.14,27
Costs for Patients With Specific Comorbidities
Four studies gave an estimate of sepsis costs in study popula-
tions with particular comorbidities.19,26,29,30 Willson et al30 found a cost 
of $36,580 in infants with sepsis who had underlying bronchiolitis. 
Robinson et al’s26 study in population of newborns born by repeat 
cesarean reported the highest average costs of all our included studies.
Two studies in patients with gastroschisis used regression 
analysis to estimate the additional costs for those patients who also 
developed sepsis19,29 compared with patients without sepsis. Both 
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studies were conducted in the United States and reported incremen-
tal costs of $21,628 and $22,380.
Costs Related to Meningitis and Meningococcal 
Septicemia
The reported costs for meningitis and meningococcal sep-
ticemia are summarized in Figure 2.
Average Cost of Hospitalization
Five studies reported acute hospitalization costs for treat-
ing meningitis, which varied from $222 in Vietnam4 to approxi-
mately $40,000 in the United States.28 The mean cost weighted by 
study sample size was $222 in lower-middle income countries and 
$13,845 in high-income countries. One study reported separate 
costs for viral and bacterial meningitis,25 with the reported costs for 
bacterial meningitis more than 3 times greater than those for viral 
meningitis ($13,154 vs. $3874).
Component Costs
Balada-Llasat et al17 was the only study that gave a break-
down of meningitis costs across different categories of health 
resource, reporting separate costs for antimicrobial therapy, diag-
nostic and laboratory tests.
Cost of Meningococcal Septicemia
One study reported a cost of $56,286 in a group of patients 
with meningococcal septicemia.20
Quality Appraisal
The quality appraisal of our selected studies is summarized 
in Table 2. There was a wide variation in the quality of scores, with 
half of studies scoring 2 or less. Seven studies scored 3, 3 studies 
scored 4, and there were no studies that scored 5. All the articles 
used an observational study design, among which, 13 used a bot-
tom-up costing methodology to calculate their costs, retrieving esti-
mates on resource utilization by surveying local health practition-
ers, local expert panels and from in-hospital accounting systems. 
Five studies did not provide a clear case definition.
DISCUSSION
Summary of Findings
Treatment of neonates and infants with sepsis or meningi-
tis represent significant costs to healthcare systems. We have con-
ducted a systematic review of studies reporting the cost of treating 
sepsis and/or meningitis in neonates and infants. Our review found 
20 studies with costs ranging from $55 to $129,632 for sepsis, $222 
to $33,635 for meningitis and a single cost estimate of $56,286 for 
meningococcal septicemia.
We found that most of the literature is concentrated in high-
income settings, with 13 studies in the United States compared with 
only 5 in middle-income countries and none at all in low-income 
countries. This highlights a major gap in the literature because treat-
ment costs varied considerably across income groups. For instance, 
all 5 middle-income countries had sepsis treatment costs that were 
TABLE 1. Summary of Included Studies, Classified by Country Income Level (n = 20)
Study Year Country
Costing  
Methodology
Cost  
Setting Perspective
Costs  
Categories Condition(s)
Case  
Ascertainment Age Range
Anh et al4 2010 Vietnam Hospital charges* Hospital Provider Single Meningitis Laboratory  
confirmed
< 1 year
Garg et al13 2005 India Unspecified ICU only Provider Single Sepsis Unspecified “Neonates”
Atif et al14 2008 Algeria Prospective  
microcosting
ICU only Provider Multiple Sepsis Clinical and  
laboratory  
confirmed
0–89 days
Liao X-P et al15 2017 China Patient-level cost 
accounts
Hospital Provider Single Sepsis Unspecified “Newborns”
Qian et al16 2008 China Prospective  
microcosting
Hospital Provider Single Sepsis Unspecified 0 – 89 days
Angus et al5 2001 United States Hospital charges* Hospital Provider Single Sepsis ICD codes < 1 year
Balada-Llasat et al17 2019 United States Hospital charges* Hospital Provider Multiple Meningitis ICD codes < 1 year
Balamuth et al18 2014 United States Hospital charges* Hospital Provider Single Sepsis ICD codes 0–59 days
Bhatt et al19† 2018 United States Hospital charges* Hospital Provider Single Sepsis ICD codes 0–28 days
Davis et al20 2011 United States Hospital charges* Hospital Provider Single Meningitis + 
meningococcal 
septicemia
ICD codes < 1 year
Donovan et al21 2013 United States Patient-level cost 
accounts
ICU only Provider Single Sepsis Unspecified < 120 days
Hartman et al22 2013 United States Hospital charges* Hospital Provider Single Sepsis ICD codes “Newborns”
Iñigo et al23 2006 Spain Government tariffs Hospital Payer Single Sepsis ICD codes < 1 year
Johnson et al24 2013 United States Patient-level cost 
accounts
ICU only Provider Single Sepsis ICD codes “Newborns”
Lieu et al25‡ 1992 United States Hospital charges* Hospital Provider Single Meningitis + 
sepsis
Unspecified 28 – 90 
days
Robinson et al26† 2010 United States Hospital charges* Hospital Provider Single Sepsis ICD codes 0–89 days
Tanihara et al27 2014 Japan Health insurance 
claims
Hospital Payer Single Sepsis ICD codes 0–95 days
Trevejo et al28 2003 United States Patient-level cost 
accounts
Hospital Payer Single Meningitis ICD codes < 1 year
Uribe-Leitz et al29† 2017 United States Hospital charges* Hospital Provider Single Sepsis ICD codes < 1 year
Willson et al30† 2003 United States Patient-level cost 
accounts
Hospital Provider Single Sepsis ICD codes < 1 year
*Ratio cost-to-charge applied.
†Costs reported for sepsis with comorbidities.
‡Costs reported separately for bacterial and viral meningitis.
ICD indicates International Classification of Diseases.
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considerably lower than those in the United States ($55 to $3607 
in middle-income countries vs. $64,047 to $129,632 in the United 
States). One factor contributing to the low number of studies from 
low- and middle-income countries might be the availability of elec-
tronic healthcare information systems that facilitate retrospective 
analysis of routinely collected patient data.
The higher reported costs for high-income countries are likely 
to reflect both greater underlying costs of healthcare production such 
as staff wages and the provision of more advanced and expensive 
treatment options. However, the majority of our studies did not report 
disaggregated costs and gave only a single estimate of the average 
cost in the form of incurred healthcare expenses in acute hospi-
talization, standard hospital care and management in neonatal and 
pediatric intensive care units (ICUs) (Table 1). Only 3 of our stud-
ies reported a breakdown of different resources categories, including 
average costs for underlying antimicrobial therapy, consultation fees 
and costs of diagnostics in treating each respective disease.14,17,27 LOS 
is also likely to be an important driver of cost differences. For sepsis, 
the average reported LOS was 24 to 72 days in high-income coun-
tries versus 4 to 14 days in low- and middle-income countries.
Heterogeneity in study populations and differences in study 
design might also have contributed to variation in the observed 
costs. Four studies focused only on the costs of treating patients in 
the ICU,13,14,21,24 whereas most included patients and costs across the 
hospital. There were also differences in the age ranges of included 
infants (Table 1.) Two studies looked at costs for preterm very low 
weight newborns,21,24 but few authors reported the proportion of 
preterm infants in their studies. A variety of different costing meth-
odologies were employed, including microcosting and top-down 
approaches. In the United States, several studies used average 
FIGURE 2. Costs related to meningitis and meningococcal septicemia. *Reported median as opposed to mean costs. ^Viral 
meningitis. ~Bacterial meningitis. CI indicates confidence interval; GDP, gross domestic product; USD, US dollars.
FIGURE 1. Costs related to sepsis. *Reported median as opposed to mean costs. ^Reported mean difference in costs for 
patients with an underlying comorbidity who developed sepsis compared to who did not. CI indicates confidence interval; 
GDP, gross domestic product; IQR, interquartile range; USD, US dollars.
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cost-to-charge ratios to estimate costs based on fees charged to 
insurers. Most cost estimates were made from a healthcare pro-
vider perspective, but some studies used a payer perspective. There 
were also differences between studies in terms of case definition 
and case ascertainment. In particular, some studies used either spe-
cific or combination International Classification of Diseases codes 
systems to ascertain cases in regional and national databases, and 
authors of such studies widely acknowledged the potential for mis-
classification errors that might bias their findings.
There were no reports of economic costs to households or 
wider society, reflecting another important gap in the literature. 
Since none of our selected studies included indirect healthcare 
costs of treating sepsis, meningitis and meningococcal septicemia, 
this could lead to an underestimation of the true costs of treating 
these conditions. Although our study was not designed to find long-
term costs associated with sequelae of sepsis and meningitis, none 
of the articles we located reported any such costs in our population 
of interest, which points to another important area of research.
The majority of studies we found included all infants with 
sepsis or meningitis who were treated within the hospital or ICU, 
but a few authors reported average costs of treating sepsis as a com-
plication in infants with underlying comorbidities, including gas-
troschisis and salmonellosis. Some of these studies reported only 
the total treatment costs, including the cost of treating underlying 
comorbidities, but 2 studies demonstrated the substantial additional 
costs of treating sepsis in these populations.
The costs reported in this study are key to economic evalua-
tions needed to understand the value of introducing vaccines against 
infections that causes sepsis and meningitis. Many of the countries 
with studies have already introduced such vaccines. Examples are 
pneumococcal conjugate vaccines (introduced in the United States 
in 2000, Japan in 2011, Algeria in 2016, parts of India in 2017 
and Spain in 2018, Haemophilus influenzae type b vaccine (United 
States in 1991, Spain in 1998, Algeria in 2008, Vietnam in 2010, 
Japan in 2011 and India in 2015) and meningococcal C (Spain in 
2000).31 Nevertheless, many of these vaccines are still not in rou-
tine immunization programs in much of the world. Also, while 
introduction of these vaccines will impact the health and economic 
burden of infectious disease, we do not expect this to influence unit 
costs of treatment amongst neonates and infants who develop sep-
sis or meningitis.
Comparison to Previous Studies
This is the first study to systematically review the costs of neo-
natal sepsis, meningitis and meningococcal septicemia globally. Two 
other systematic reviews of the cost of sepsis or meningitis have been 
published. One review examined the cost of meningitis in low- and mid-
dle-income settings.12 This gave a cost range from $42 to $9300 com-
pared with $222 in the only low- or middle-income country study (in 
Vietnam) in our review. In addition, we also found reported meningitis 
costs of $3874 to $39,169 in high-income countries beyond the scope 
of the previous review. A second review examined the cost of sepsis in 
all countries, finding a cost range of $20,795 to $40,835,32 compared 
with $55 to $129,632 in our review. Our review identified more studies 
specifically reporting costs amongst infants and neonates (16 compared 
with 1 study) and was carried out over an unrestricted timeframe, in 
contrast to the 10-year period between 2005 and 2015 for the published 
review. We also observed a markedly different lower bound in the cost 
range because our review included studies from lower-income settings. 
Neither of the previous reviews examined the costs of meningococcal 
septicemia, for which we found a single reported estimate of $56,286. 
This was a considerably higher than the costs reported for meningitis 
alone but fell within our range of sepsis-related costs.
Limitations
One challenge in this review was the difficulty in retriev-
ing costs for neonates and infants in studies covering a range of 
ages, despite writing to authors to request further information. This 
highlights the importance of reporting cost estimates by age group 
in future studies. This is particularly important since neonatal sep-
sis and meningitis imposes considerably higher costs than treating 
these conditions in older children.4,5 For instance, Anh et al4 found 
the average cost of treating meningitis was $190 for infants under 5 
months compared with $114 for children 59 months of age.
Another challenge was with the consistency and clarity of 
case definitions for sepsis and meningitis. In particular, sepsis was 
not consistently defined and was sometimes used interchangeably 
with invasive bloodstream infections. In 4 of the included studies, 
there was no clearly specified case definition at all. To improve 
comparability future research needs to apply consistent case defi-
nitions for meningitis and sepsis, such as the “Third international 
consensus definitions for sepsis and septic shock,”7 although these 
are not yet fully applicable for neonates.33
TABLE 2. Summary of Study Quality Appraisal
Study Year Country
Bottom-Up  
Costing
Sample Size  
Over 100
Direct and  
Indirect Costs
Case Definitions  
Included
Controlled for  
Acknowledged Bias
Quality 
Score
Angus et al5 2001 United States X X  X X 4
Anh et al4 2010 Vietnam X X  X X 4
Atif et al14 2008 Algeria X   X X 3
Balada-Llasat et al17 2019 United States X X  X  3
Balamuth et al18 2014 United States X X  X  3
Bhatt et al19 2018 United States  X  X  2
Davis et al20 2011 United States    X X 2
Donovan et al21 2013 United States X   X X 3
Garg et al13 2005 India X     1
Hartman et al22 2013 United States X X  X  3
Iñigo et al23 2006 Spain X X  X X 4
Johnson et al24 2013 United States X X  X  3
Liao et al15 2017 China  X    1
Lieu et al25 1992 United States      0
Qian et al16 2008 China X X    2
Robinson et al26 2010 United States    X  1
Tanihara et al27 2014 Japan X X  X  3
Trevejo et al28 2003 United States      0
Uribe-Leitz et al29 2017 United States    X X 2
Willson et al30 2003 United States    X  1
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A further limitation is that we were unable to generate formal 
pooled cost estimates. The number of included studies was consid-
ered too few to perform meta-analysis given differences in reported 
estimate types (mean vs. median), the number of studies that did 
not report uncertainty intervals and heterogeneity between studies.
Overall, a significant number of the studies we identified 
were of quite poor quality and were limited in the description they 
provided about their costing methodology. For example, the costing 
perspective was rarely defined explicitly, there was varying levels of 
detail about how reported costs were calculated and many studies 
did not report uncertainty ranges for their estimates. This was espe-
cially seen in studies that did not primarily focus on conducting a 
detailed costing analysis and where costing was a secondary outcome 
in broader epidemiological studies and economic evaluations. Utili-
zation of references cases and reporting guidelines for costing and 
economic evaluations would increase consistency and transparency 
of economic methods and the comparability of reported costs.34,35
Conclusions
Sepsis and meningitis in neonates and infants are associ-
ated with substantial costs to health care systems. Reported costs 
showed significant variation between different settings, although 
methodologic variations between studies limit the comparability 
of individual cost estimates. Evidence gaps identified by our study 
highlight the need for (1) more research on the cost of treating 
sepsis and meningitis in neonates and infants in low- and middle-
income settings and (2) more studies that measure the economic 
costs of illness borne by families and wider society. Further-
more, to maximize the value of future studies, researchers need to 
improve consistency in case definitions and utilize comparable and 
well-described economic methods.
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